Consistent with our findings, a recent study demonstrated that AR re‐activation can be achieved by CDK9‐mediated phosphorylation and that PCa can be co‐targeted by CDK9 inhibitor and AR antagonist [19]. Here, CDK9 is linked to posterior cortical atrophy.